
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : NYU Langone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : NYU Langone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
